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Abstract
AIM: To investigate matrix metalloproteinases (MMPs) 
and their tissue inhibitors (TIMPs) in pouch mucosa of 
pediatric onset ulcerative colitis (UC).
METHODS: In this cross-sectional study, 28 patients 
with pediatric onset UC underwent ileal pouch biopsy 
13 years (median) after proctocolectomy. Expression of 
MMPs-3, -7, -8, -9, -12 and -26 and TIMPs-1, -2 and -3 
in samples was examined using immunohistochemichal 
methods, and another biopsy was used to evaluate the 
grade of histological inflammation. Two investigators 
independently graded the immunohistochemical speci-
mens in a semiquantitative fashion, using a scale mark-
ing staining intensity as follows: 0 = less than 20 posi-
tive cells; 1 = 20-50 positive cells; 2 = 50-200 positive 
cells; 3 = over 20 positive cells. Fecal calprotectin and 
blood inflammatory markers [serum C-reactive protein 
(CRP) and erythrocyte sedimentation rate] were deter-
mined during a follow-up visit to examine correlations 
between these markers and the expression of MMPs 
and TIMPs.
RESULTS: Of the 28 patients with pediatric onset UC, 
nine had not experienced pouchitis, whereas thirteen 
reported a single episode, and six had recurrent pou-
chitis (≥ 4 episodes). At the time of the study, six pa-
tients required metronidazole. In all of the others, the 
most recent episode of pouchitis had occurred over one 
month earlier, and none were on antibiotics. Only four 
samples depicted no sign of inflammation, and these 
were all from patients who had not had pouchitis. Two 
samples were too small to determine the grade of in-
flammation, but both had suffered pouchitis, the other 
recurrent. No sample depicted signs of colonic metapla-
sia. Most pouch samples showed expression of epithe-
lial (e) and stromal (s) MMP-3 (e, n  = 22; s, n = 20), 
MMP-7 (e, n = 28; s, n = 27), MMP-12 (e, n  = 20; s, n  
=24), TIMP-2 (e, n  = 23; s, n = 23) and MMP-3 (e, n  = 
23; s, n = 28) but MMP-8 (e, n = 0; s, n  = 1), MMP-9 (e, 
n  = 0; s, n  = 9) and MMP-26 (e, n  = 0; s, n  = 3) and 
TIMP-1 (n  = 0, both) were lacking. In samples with 
low grade of inflammatory activity, the epithelial MMP-3 
and MMP-7 expression was increased (r  = -0.614 and 
r  = -0.472, respectively, P  < 0.05 in both). MMPs and 
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TIMPs did not correlate with the markers of inflamma-
tion, fecal calprotectin, erythrocyte sedimentation rate, 
or CRP, with the exception of patients with low fecal 
calprotectin (< 100 µg/g) in whom a higher expression 
of epithelial MMP-7 was found no differences in MMP- 
or TIMP-profiles were seen in patients with a history 
of pouchitis compared to ones with no such episodes. 
Anastomosis with either straight ileoanal anastomosis 
or ileoanal anastomosis with J-pouch did depict differ-
ences in MMP- or TIMP-expression.  
CONCLUSION: The expression of MMPs pediatric UC 
pouch in the long-term shares characteristics with in-
flammatory bowel disease, but inflammation cannot be 
classified as a reactivation of the disease.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
In children, ulcerative colitis (UC) appears to present 
more aggressively than in adults[1,2]. The number of  pedi-
atric UC cases requiring colectomy within the first decade 
after diagnosis may reach 24%[1]. Restorative proctocolec-
tomy with ileoanal anastomosis (IAA) and an ileal pouch-
anal anastomosis is the surgical treatment of  choice in 
UC[2].
In proctocolectomized patients, pouchitis is a com-
mon complication, and over two thirds of  children un-
dergoing proctocolectomy will suffer at least one episode 
of  pouchitis during the following decade[2]. Yet, studies 
on pouchitis in children are limited. Pouchitis is an id-
iopathic inflammatory condition of  the ileal reservoir 
occurring frequently after colectomy with IAA[3]. The 
etiology of  pouchitis is poorly understood, but it is asso-
ciated with risk factors such as extensive colonic disease 
preoperatively and young age at proctocolectomy[4]. The 
incidence of  pouchitis is higher in UC than in familial 
adenomatous polyposis[5], and pouchitis has been consid-
ered a recurrent form of  colitis[5,6]. Ileal pouch mucosa 
may acquire colonic characteristics[7,8], and colonic meta-
plasia is more pronounced in patients with pouchitis[9]. 
This mucosal transformation could have a role in the 
pathogenesis of  pouchitis, possibly allowing the recur-
rence of  inflammatory bowel disease (IBD) and may rep-
resent a novel manifestation IBD[7-9].
Matrix metalloproteinases (MMPs) are a family of  24 
zinc-dependent enzymes implicated in mucosal damage 
in IBD[10]. MMPs take part in normal mucosal defense, 
and are capable of  degrading extracellular matrix and 
basement membrane proteins in tissue remodeling pro-
cesses both in normal and in pathological conditions[10]. 
In IBD, MMP-9 is the most abundantly expressed MMP, 
and it shows increased activity in inflamed UC mucosa[11]. 
Other MMPs have also been linked to inflammation 
severity in IBD, such as MMP-7[12]. Our group has dem-
onstrated enhanced MMPs-1, -3 and -7 expression in 
IBD, and shown MMP-10 expression in IBD granulation 
tissue[13,14]. In pediatric IBD, we have described increased 
expression of  epithelial MMP-10 and stromal tissue in-
hibitor (TIMP)-3[15].
The pathogenesis of  pouchitis is unknown, and it 
is debated whether or not the inflammation is similar 
to that found in UC, or whether it is inflammation of  a 
novel kind. The management of  pouchitis by antibiot-
ics and probiotics is widely accepted. Yet, according to a 
recent review, antibiotics are not significantly better than 
a placebo, compared to the high dose probiotics. By alter-
ing the endogenous flora and the expression of  inflam-
mation parameters, as well as competing with pathogens 
for receptor binding, nutrients, and growth factors, the 
high dose probiotics are effective in treatment of  pou-
chitis[16]. The occurring inflammation and acquisition of  
colonic characteristics[7,8] inspires an interest in the MMP 
and TIMP-profile of  pouch. We are aware of  only two 
studies of  MMP expression in pouchitis in adults[17,18]. 
Expression of  MMP-1 and MMP-2 in pouchitis is differ-
ent from normal ileal mucosa, but is similar to expression 
in active UC colitis[17]. We examined the MMP and TIMP 
profiles of  pouch patients who had undergone procto-
colectomy in their childhood or adolescence, and to find 
clues to the type of  inflammation appearing in the pouch. 
It is important to determine whether this inflammation is 
IBD-like or of  a novel kind, to appropriately prevent and 
manage pouchitis in the future.
MATERIALS AND METHODS
Patients and setting
Between 1985 and 2005, 81 pediatric patients with UC un-
derwent proctocolectomy with ileal anastomosis at Tam-
pere University Hospital or Children’s Hospital, Helsinki. 
Of  these colectomized patients, one died of  an unrelated 
cause and one emigrated. Thus, 79 patients were traced 
from the database of  the Population Register Centre and 
contacted by mail during 2006. Thirty-five patients agreed 
to participate for a follow up visit described elsewhere 
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in detail[2], but seven had been rediagnosed as Crohn’s 
disease (CD). The 28 UC cases were included in this 
study (Table 1). All proctocolectomies included transanal 
mucosectomy and a hand-sewn anastomosis. Twenty-
one patients had an IAA with J-pouch, and 7 had straight 
ileoanal anastomosis (SIAA). Patients filled out a ques-
tionnaire surveying the current diagnosis, complications, 
medical therapy and pouchitis. To map the latter two, we 
asked about medications to control stool frequency, and 
the history and treatment of  pouchitis. During the outpa-
tient visit, biopsy of  the pulled through ileum, and stool 
and blood samples were obtained. The Ethical Commit-
tee of  the Helsinki University Hospital approved the and 
the participants (or their guardians) gave informed con-
sent.
Fifteen UC patients had other chronic illnesses: scle-
rosing cholangitis, active hepatitis, gastroeosophageal re-
flux, gallstones, rheumatoid arthritis, sacroiliac-joint arthri-
tis, knee arthritis, hyperthyroidism, cardiac arrythmias, psy-
chiatric illness, endometriosis, fibromyalgia, osteoporosis, 
asthma, atopic skin and contact allergy. Specific medica-
tions at the time of  the study are shown in Table 2. Post-
operatively, 18 (64%) UC patients had received antibiotics 
as treatment for pouchitis, and of  these, 7 (25%) also had 
received corticosteroids. 
Blood inflammatory markers and fecal calprotectin 
Inflammation biomarkers in blood [erythrocyte sedimenta-
tion rate, erythrocyte sedimentation rate (ESR), and serum 
concentration of  C-reactive protein (CRP)] and fecal cal-
protectin (quantitative enzyme immunoassay, PhiCal test, 
Calpro AS, Oslo, Norway) were routinely determined[18]. 
For immunohistochemistry, biopsies from pouch were 
used. The histological grade of  inflammation in the sam-
ples was assessed according to the scoring system for pa-
thological changes in the ileal reservoir mucosa[7,19].
Immunohistochemistry 
One biopsy was analyzed for the grade of  histological 
inflammation, the other biopsy was used for MMP immu-
nohistochemistry. Immunohistochemistry was performed 
using sreptavidin-biotin-peroxidase complex technique 
(DakoCytomation, StreptABComplex/HRP Duet, Mouse/
Rabbit, Glostrup, Denmark; and Elite goat Vectastain ABC 
kit, Vector laboratories, Burligame, CA, United States) or 
the antibody-polymer detection technique (ImmPRESS 
universal reagent, Anti-Mouse/Rabbit IG, Vector labora-
tories Burligame, CA, United States). Diaminobenzidine 
or NovaRED (Vector Laboratories) were used as chromo-
genic substrates and Mayer’s hematoxylin as counterstain. 
Monoclonal antibodies were used to stain for MMP-7 
(1:600, MAB3315, Millipore, Temecula, CA, United 
States)[15], MMP-8 (1:100, IM38, Calbiochem, La Jolla, CA, 
United States)[15], MMP-9 (1:100, MS-569-P1, Lab Vision 
Corporation Neomarkers, Fremont, CA, United States)[15], 
TIMP-1 (1:50, IM63, Calbiochem)[15], TIMP-2 (1:600, 
IM56, Calbiochem) and TIMP-3 (1:300, IM43L, Calbio-
chem)[15]. Polyclonal antibodies were used for MMP-3 
(1:50, ab32607, Abcam Ltd, Cambridge, United King-
dom), MMP-12 (1:80, sc-12361, Santa Cruz Biotechnol-
ogy, CA, United States)[15] and MMP-26 (1:120, a gift from 
Professor Isaka K, Tokyo Medical University)[15]. MMP-8 
and MMP-9 were pretreated with 1% trypsin solution for 
30 min at 37 ℃. MMP-3, MMP-7, MMP-26, TIMP-1, 
TIMP-2 and TIMP-3 were pretreated in a 95 ℃ water 
bath for 30 min (Dako retrieval solution pH 6; Dakocyto-
mation). MMP-12 required no pre-treatment. The incuba-
tion conditions for the antibodies were: 4 ℃ overnight for 
MMPs-7, -9, -12 and TIMPs-1, -2, -3; 1 h 45 min at 37 ℃ 
for MMP-8 and 1 h at room temperature for MMP-3 
and MMP-26. For negative controls, parallel sections of  
the same samples were processed using preimmune sera 
or normal rabbit or mouse immunoglobulin. As positive 
controls, we used formalin fixed, paraffin embedded sec-
tions of  hailey-hailey, pyoderma gangrenosum and derma-
titis herpetiformis (MMP-3), adenocarcinoma (MMP-7), 
squamous cell cancer (MMP-8), chronic wounds (MMP-9 
and TIMP-2 and -3), foreign body reaction (MMP-12), 
endometrium (MMP-26), and pyoderma gangrenosum 
(TIMP-1). Immunohistochemical specimens were graded 
independently by two different investigators (Mäkitalo L, 
Piekkala M) in a semiquantitative fashion under a light-
Table 1  Patient characteristics
Patient characteristics Median (range)
Number of patients (male)   28 (9)
Age (yr); median (range)
   At diagnosis   12 (1-15)
   At operation   13 (2-19)
   At the time of study   25 (8-41)
   Duration from surgery to study   13 (4-22)
Clinical inflammation markers; mean (range)
   Fecal calprotectin (µg/g) 371 (12-2859)
   ESR (mm/h)   14 (2-69)
   CRP (mg/L)     3 (0-19)
ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein.
Table 2  Medications at the time of study
Intestinal inflammation              n
5-ASA              1
5-ASA + antibiotics              1
Antibiotics              5
Bowel function
  To decrease bowel motility             10
  To increase bulk mass              1
  Analgesics              1
  Lactic acid bacteria              1
Other chronic illnesses
  Cholangitis              1
  Mood stabilizing agents              2
  Antibiotics for acne              1
  Gastro-esophageal reflux              1
  Cardiac arrythmias              1
  Infertility              1
  Asthma              1
  Hyperthyroidism              1
5-ASA: 5-Aminosalicylic acid formulations.
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field microscope at × 100 magnification using a scale 
marking staining intensity as follows: 0 = less than 20 
positive cells; 1 = 20-50 positive cells; 2 = 50-200 positive 
cells; 3 = over 200 positive cells[15,20]. The identity of  the 
cell types producing each MMP or TIMP was confirmed 
together with an experienced pathologist (Karikoski R).
Statistical analysis
Non-parametric Mann-Whitney’s test, Spearman’s correla-
tion test and independent samples t test were performed 
with the SPSS 17.0 for Windows (Chicago, IL) to investi-
gate the significance of  results. A P < 0.05 was considered 
significant.
RESULTS
Of  the 28 patients with pediatric onset UC, nine (32.1%) 
had not experienced pouchitis, whereas 13 (46.4%) re-
ported a single episode, and six (21.4%) had recurrent 
pouchitis (≥ 4 episodes)[19]. Six patients were on metro-
nidazole medication at the time of  the study (Table 2) 
one of  them also on a 5-aminosalicylic acid formulation 
and showed inflammation of  grades 1 to 3[7,20]. In all the 
others the last episode of  pouchitis had occurred more 
than one month earlier, in most cases several months ear-
lier and they were not on antibiotics. Only four samples 
(14%) depicted no signs of  inflammation, and these were 
all from patients who had not experienced pouchitis. Of  
the 19 patients who had experienced pouchitis, 7 showed 
mild inflammation, 3 depicted moderate and 7 severe in-
flammation in the biopsy. Two samples were too small to 
determine the grade of  inflammation, but both had suf-
fered pouchitis, the other recurrent. No sample depicted 
signs of  colonic metaplasia.
Expression of  MMP-3 was seen in the majority of  
the samples in the epithelium and in stroma in plasma 
cells, macrophages and eosinophils (Table 3 and Figure 
1A, B). Also, MMP-3 positive endothelium was observed 
(Figure 1B1, B4). Epithelial MMP-7 was present in all 
samples, and stromal MMP-7 in 27 samples in plasma 
cells, macrophages and eosinophils, as well as endothe-
lium (Table 3 and Figure 1C, D). Conversely, stromal 
MMP-9 was present in 9 samples in macrophages, plasma 
cells and eosinophils, and in intraepithelial neutrophils, 
but no positive enterocytes could be found (Table 3 and 
Figure 2D, E). MMP-12 was found in the majority of  the 
samples in the epithelium and in stroma in macrophages, 
plasma cells, and eosinophils and intraepithelial neutro-
phils (Table 3 and Figure 2F, G1). Stromal cells showed 
positivity for MMP-26 in 3 samples in neutrophils and 
plasma cells but epithelial cells were negative for this 
MMP (Table 3 and Figure 2B). MMP-26 positive neutro-
phils were present in blood vessels (Figure 2B3). TIMP-2 
was positive in the majority of  samples in the epithelium 
and in stromal cells including plasma cells, eosinophils 
and macrophages (Table 3 and Figure 1E, F). TIMP-3 
was found in enterocytes in 23 (82%) samples and in all 
samples in plasma cells and macrophages in stroma (mean 
2.39) (Table 3 and Figure 1G). Endothelial cells were 
also positive for TIMP-3 (Figure 1G1, G2). Expression 
of  MMP-8 and TIMP-1 was generally absent, although a 
few neutrophils in stroma were positive for MMP-8 and 
cryptal cells showed positivity for TIMP-1 (Figure 2A, C). 
No differences in MMP- or TIMP-profiles were seen 
when comparing samples from patients that had expe-
rienced pouchitis (single or several episodes) (n = 19) 
to ones that had not (n = 9). The same was true when 
performing comparisons related to the frequency of  pou-
chitis (data not shown). When comparing patients with 
SIAA to those with SIAA with J-pouch, no differences in 
MMP- and TIMP-expression profiles or the frequency of  
pouchitis episodes could be found.
MMPs and TIMPs did not generally correlate with 
inflammation markers fecal calprotectin, ESR and CRP. 
However, patients considered have no active inflam-
mation (fecal calprotectin < 100 µg/g) showed higher 
expression of  epithelial MMP-7 (Figure 1C) in their 
pouch biopsies compared to samples from those with 
active inflammation (fecal calprotectin ≥ 100 µg/g)[21] 
(Figure 1D1; means 1.75 vs 1.14, P = 0.020, respectively). 
Table 3  Expression profiles of  matrix metalloproteinases and 
tissue inhibitor of matrix metalloproteinase in ulcerative colitis 
samples
Number of positive samples mean±SEM1
MMP-3
   Epithelium 22 0.93 ± 0.114
   Stroma 20 1.25 ± 0.183
MMP-7
   Epithelium 28 1.36 ± 0.092
   Stroma 27 1.89 ± 0.149
MMP-8
   Epithelium  0 0.00 ± 0.000
   Stroma  1 0.04 ± 0.036
MMP-9
   Epithelium  0 0.00 ± 0.000
   Stroma  9 0.32 ± 0.090
MMP-12
   Epithelium 20 0.75 ± 0.098
   Stroma 24 1.46 ± 0.141
MMP-26
   Epithelium  0 0.00 ± 0.000
   Stroma  3 0.11 ± 0.060
TIMP-1
   Epithelium  0 0.00 ± 0.000
   Stroma  0 0.00 ± 0.000
TIMP-2
   Epithelium 23 0.89 ± 0.094
   Stroma 23 1.75 ± 0.203
TIMP-3
   Epithelium 23 1.04 ± 0.120
   Stroma 28 2.39 ± 0.130
Histology
   Neutrophils 0.85 ± 0.154
   Lymphocytes 1.07 ± 0.185
   Eosinophils 1.04 ± 0.167
   Villus atrophy 1.19 ± 0.227
   Grade 1.95 ± 0.203
1mean calculated from values: 0 = less than 20 positive cells; 1 = 20-50 posi-
tive cells; 2 = 50-200 positive cells; 3 = over 200 positive cells; Grade: Grade 
of inflammation; MMPs: Matrix metalloproteinases; TIMP: Tissue inhibitor 
of matrix metalloproteinase.
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The grade of  inflammation in histological assessment[7] 
correlated negatively with epithelial MMP-3 (Table 4) (r 
= -0.614, P = 0.002) (Figure 1A, B1) and MMP-7 (r = 
-0.472, P = 0.027) (Figure 1C, D1).
DISCUSSION
In pediatric patients, these MMPs and TIMPs have not 
been studied in pouches, and in adults, reports of  only 
MMPs 1-3 and MMP-9 exist[17,18]. This study reports for 
the first time expression of  MMPs-7, -8, -12, TIMP-2, 
and TIMP-3 in ileal reservoir mucosa. In long-term, the 
MMP- and TIMP-profiles in pouch demonstrate similari-
ties with IBD, but profiles in pouch cannot be said to 
replicate those in UC colon.
In adult inflamed and non-inflamed pouches of  UC 
patients, MMP-3 activity is considered weak[18]. Here, 
MMP-3 was present in all but few samples in epithe-
lium and stroma. In pediatric IBD, MMP-3 is elevated 
in endoscopically abnormal colon compared to healthy 
colon[22]. MMP-3 plays an important role in T-cell- and 
tumor necrosis factor (TNF)-α-mediated gut injury[23,24], 
and IBD gut plasma cells produce more MMP-3 than 
those of  healthy controls[25]. Here, expression of  epithe-
lial MMP-3 associated with the degree of  inflammation, 
complying with animal studies where lack of  MMP-3 
associated with impaired wound healing[26]. The present 
findings suggest that MMP-3 is an important MMP in 
pouch mucosa, resembling IBD. However, its relationship 
to the development of  pouchitis is unclear. Similar to 
MMP-3, we found TIMP-3 in a large number of  cells in 
stroma, expression paralleling reports in IBD colon[15,20]. 
Figure 1  Matrix metalloproteinases-3, matrix metalloproteinases-7 and tissue inhibitor of matrix metalloproteinase-2 in lower (A, C, E1, respectively) and 
higher grade of inflammation and calprotectin levels (B1, D1, F, respectively), tissue inhibitor of matrix metalloproteinase-3 in pouch (G1). Black solid arrows 
plasma cells, black dotted arrows macrophages, red solid arrows eosinophils and red dotted arrows endothelium. Scale bars: 15 µm (A, B1, C, D1, E1, F, G1); 7.5 µm 
(B2-B4, D2, D3, E2, G2, G3). Stainings were performed using diaminobenzidine or NovaRED as chromogenic substrates and Mayer’s hematoxylin as counterstain. 
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Our group has noted that in intestinal ulcerations in IBD, 
TIMP-3 is expressed in a greater number of  stromal 
cells compared to normal intestine[14]. TIMP-3 inhibits 
TNF-α[27], an important cytokine in IBD inflammation[28], 
and elevated TIMP-3 protein is likely to associate with 
elevated TNF-α-levels as seen in a human colonic cell 
line[29]. Also, abundant TIMP-3 expression in stroma in 
pouch resembles that found in pediatric UC[15], possibly 
preventing destructive activity as suggested for other au-
toimmune diseases[30].
Of  the other MMPs, expression of  MMP-7, MMP-8, 
and MMP-9 was not IBD-like. Unlike MMP-8 and MMP-9, 
stromal MMP-7 was present in notable numbers of  cells in 
almost all samples. We recently examined MMP-7 expres-
sion in pediatric IBD colon, and found weaker expression 
in epithelium in UC samples[15]. Here, MMP-7 was found 
in a smaller number of  epithelial cells in samples with 
higher grade of  histological inflammation and fecal cal-
protectin levels. This contradicts earlier results in UC[12,31]. 
However, MMP-7 contributes to intestinal wound closure 
but over-expression may delay epithelial wound heal-
ing[32]. Epithelial expression in pouch thus may be due to 
a regenerative process. MMP-7 has also been suggested 
to aid the growth of  myofibroblasts and their function[33] 
and stromal MMP-7 may take part in maintaining muco-
sal homeostasis. In normal colon, MMP-8 is undetect-
able[10] but it may be involved in ulcer formation[34] as 
elevated levels are found in ulcer bases of  both UC and 
CD[10]. We are not aware of  previous studies of  MMP-8 
in pouch mucosa, but in our study, MMP-8 was generally 
absent from pouches. MMP-9 is important in IBD-relat-
ed inflammation, and has also been shown to correlate 
Figure 2  matrix metalloproteinases-8 (A1), matrix metalloproteinases-9 (D1, E1), matrix metalloproteinases-12 (F1, G), matrix metalloproteinases-26 (B1) 
and tissue inhibitor of matrix metalloproteinase-1 (C) in pouch. Inset g’ added to figure from another sample, not shown in here in lesser magnification. Arrow-
heads depict neutrophils, black solid arrows plasma cells, black dotted arrows macrophages, red solid arrows eosinophils. Scale bars: 15 µm (A1, B1, C, D1, E1, 
F1,G); 7.5 µm (A2, B2, B3, D2, D3, E2, F2, F3). Stainings were performed using diaminobenzidine or NovaRED as chromogenic substrates and Mayer’s hematoxylin 
as counterstain. Images were obtained using a light-field microscope, and edited using Adobe Photoshop 7.0 (Adobe Systems Incorporated).
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Table 4  Matrix metalloproteinases and  tissue inhibitor of matrix metalloproteinase that correlated with inflammation indicators
Inflammation indicators Correlation coefficients values
MMP-3 MMP-7 MMP-12 TIMP-2
Epithelium Epithelium Epithelium Stroma Epithelium
Fecal calprotectin NS NS -0.350 NS NS
C-reactive protein NS NS NS -0.422 NS
Grade of inflammation -0.614 -0.472 NS NS -0.420
NS: Not significant; MMPs: Matrix metalloproteinases; TIMP: Tissue inhibitor of matrix metalloproteinase. Correlations were calculated using Spearman’s 
correlation test.
pouchitis, but most samples depicted inflammation with 
concurrent elevated calprotectin. It seems reasonable that 
since there was no variation in MMP- or TIMP-profile 
according to the frequency of  pouchitis, that inflamma-
tion markers depict very little correlation with MMPs. 
While even a longer follow-up may be necessary to fur-
ther investigate the nature of  pouch mucosa, the strength 
of  the study is the long follow-up of  the patients with 
pediatric onset disease, up to two decades after surgery. 
In conclusion, in long-term, MMP expression in pouch 
shares characteristics with UC, but inflammation cannot 
be classified as a reactivation per se. Expression of  MMP-3 
and TIMP-3 in pouch resembles that of  IBD, but the lack 
of  MMP-9 contradicts an IBD-like pathomechanism. To 
the best of  our knowledge, this study is the first to show 
that MMPs-7, -12, and TIMP-2 are also important in 
pouch mucosa. Further studies on the role of  MMP pro-
files in etiopathology and the development of  pouchitis 
in pediatric onset UC are warranted.
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Background
Approximately 24% of pediatric ulcerative colitis (UC) patients undergo colec-
tomy with ileal pouch anal anastomosis within the first decade after diagnosis. 
Pouchitis is the most common complication occurring in approximately two 
thirds of the patients at least once during the following decade. The etiology 
of pouchitis is unknown and it is debated whether the inflammation is a novel 
kind or similar to that of found in UC. Matrix metalloproteinases (MMPs) have 
been linked to both physiological and pathological event in inflammatory bowel 
disease (IBD) mucosa.
Research frontiers
In pediatric IBD MMP 10 and tissue inhibitor of matrix metalloproteinase (TIMP) 
3 have been linked to the colonic inflammation. Most abundantly expressed 
MMP in IBD-like inflammation is MMP-9 and the MMP-7 is linked to the severity 
of inflammation. There are no reports of MMP expression in pediatric pouch. 
Thus, the authors studied the expression of MMPs-3, -7, -8, -9 and -12 and 
TIMPs-1, -2, and -3 from the biopsies of pediatric UC patients’ pouches to find 
MMPs and TIMPs specific to the pediatric pouchitis. 
Innovations and breakthroughs
The expression of MMPs and TIMPs in pediatric pouches has not been studied 
previously and adult reports of only MMPs-1, -3 and -9 exist. This study, for first 
time, reports the epithelial and stromal expression of MMP-3, -7 -12, TIMP-2, 
and -3 and the lack of MMPs-8, -9, -26, and TIMP-1 expression in pediatric ileal 
reservoirs. The presence of MMPs-3, -12 and TIMP-3 share some similarities 
with IBD, but the lack of MMP-9 contradicts the IBD-like inflammation. 
Applications
By understanding the MMP- and TIMP-profile of pouch mucosa, this study 
takes part in characterizing molecular environment in pouch, which may in turn 
aid in finding specific biomolecular targets for treatment of pouchitis.
Terminology
UC is chronic disease of the mucosa of the colon and the rectum characterized 
by bloody diarrhea, abdominal pain, and weight loss. Pouchitis is the inflamma-
tion of the ileal reservoir that is made after colectomy to avoid permanent os-
tomy. MMPs are a family of 24 zinc-dependent enzymes that are capable to de-
grade nearly all extracellular matrix and basement membrane proteins and take 
part to both normal and pathological tissue remodeling. TIMPs inhibit the action 
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with disease activity[10]. We found expression of  MMP-9 
in only a few samples, not suggestive of  IBD-like inflam-
mation.
In our study, MMP-12 was found in almost all pouch 
samples, although it is not expressed in normal adult 
ileum[14,35]. While it’s role in IBD is unknown, this MMP 
may take part in macrophage migration and can activate 
TNF-α[10,36]. MMP-12 has been proposed to be a final 
step in tissue injury in celiac disease[37] and might have a 
pathological role in pouch mucosa. Its expression sug-
gests that pouch mucosa is dissimilar to normal ileal mu-
cosa, even in the absence of  inflammation. 
In the present study, expression of  MMP-26 was rare. 
We have proposed that immunosuppressive drugs modu-
late disease activity in CD by downregulating MMP-26[20]. 
It is found in the colon of  pediatric IBD patients[15], but 
also in healthy ileum[38], and expression is not IBD-specif-
ic. TIMP-1 is present in greater amount in inflamed adult 
IBD than in healthy mucosa[31], whereas in pediatric IBD, 
we have reported weak TIMP-1 expression[15]. We found 
no expression of  TIMP-1 in the pouch, but epithelial and 
stromal TIMP-2 was found in most samples. Structural 
features of  TIMP-2 suggest that it is expressed in con-
stant amount[39], and it has been reported to be present 
in normal-appearing IBD mucosa, with no significant 
increase in inflamed mucosa[40]. Expression of  MMP-26, 
TIMP-1 and TIMP-2 were inconclusive, neither support-
ing of  contradicting IBD-etiology.
Taken together, earlier studies on MMPs and TIMPs 
in pouch are scarce, but in adults elevated MMP-1 and 
MMP-2 have been found in pouchitis mucosa[17]. Due 
to small sizes of  the biopsy and limited stainable slides, 
these MMPs were not studied here. The presence of  
MMP-3 and TIMP-3 in our samples is comparable to 
findings in IBD. In line with this, MMP-12 is detected in 
active IBD but not in normal ileum[14,35,41], and here, ex-
pression of  MMP-12 in pouch suggests altered mucosa. 
The lack of  proper MMP-8 and MMP-9 expression in 
the pouch, however, contradicts IBD-related inflamma-
tion, as does the expression profile of  MMP-7. 
The results here are based on immunohistochemistry 
only, a limitation of  this study, and further research using 
other techniques, e.g., Western blotting and polymerase 
chain reaction, would be necessary to verify the findings. 
We could not include a side-by-side analysis of  samples 
from active UC and normal ileum and colon. Parallel 
analysis of  ileal and colonic samples is challenging, as the 
follow up lasted until early adulthood. It is possible, that 
the use of  medication in some cases may affect the ex-
pression of  MMPs and TIMPs. It has been put forth, that 
probiotic use - that seems to elevate interleukin-10 in the 
gut-might downregulate the expression of  MMP activity 
in the pouch mucosa and alter the expression of  other 
proinflammatory cytokines[18], but this finding needs 
more systematic studies. However, due to small sample 
size, we focused on comparing the expression patterns 
with established markers depicting the activity of  inflam-
mation. Interestingly, we found no differences in MMP 
or TIMP expression depending on the frequency of  
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of MMPs but the actions of TIMPs are not restricted to the MMP-inhibition, they 
also modulate other cellular processes.
Peer review
This is a study on matrix metalloproteinases and their tissue inhibitors in pouch 
mucosa of pediatric onset UC. This is a good study and the topic is so impor-
tant because pouchitis is often seen in those who have undergone ileal pouch-
anal anastomosis.
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